<DOC>
	<DOCNO>NCT02921061</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose decitabine give together filgrastim , cladribine , cytarabine , mitoxantrone hydrochloride treat patient acute myeloid leukemia myelodysplastic syndrome newly diagnose , come back , respond treatment . Drugs use chemotherapy , decitabine , cladribine , cytarabine , mitoxantrone hydrochloride work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Colony-stimulating factor , filgrastim , may increase production blood cell may help immune system recover side effect chemotherapy . Decitabine , filgrastim , cladribine , cytarabine , mitoxantrone hydrochloride may work well treat patient acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Decitabine , Filgrastim , Cladribine , Cytarabine , Mitoxantrone Hydrochloride Treating Patients With Newly Diagnosed , Relapsed , Refractory Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate maximum tolerate dose ( MTD ) decitabine use sequentially concomitantly filgrastim , cladribine , cytarabine , mitoxantrone hydrochloride ( G-CLAM ) independently patient newly diagnose relapsed/refractory acute myeloid leukemia ( AML ) high-risk myelodysplastic syndrome ( MDS ) . SECONDARY OBJECTIVES : I . Evaluate , within limit phase I study , disease response duration remission . II . Describe , within limit phase I study , toxicity profile study regimen . III . Describe , within limit phase I study , impact study regimen quality life . OUTLINE : This dose de-escalation study decitabine . Patients randomize 1 2 group . GROUP I ( PRIMED ) : Patients receive decitabine intravenously ( IV ) 1 hour day -14 -5 . Patients also receive filgrastim subcutaneously ( SC ) day 0-5 , cladribine IV 2 hour day 1-5 , cytarabine IV 2-4 hour day 1-5 mitoxantrone hydrochloride IV 60 minute day 1-3 . GROUP II ( CONCURRENT ) : Patients receive decitabine IV 1 hour day 1-10 . Patients also receive filgrastim , cladribine , cytarabine , mitoxantrone hydrochloride Group I . In group , treatment repeat every 10 day 2 course absence disease progression unacceptable toxicity . CONSOLIDATION THERAPY : Beginning 6 week achieve complete remission ( CR ) /CR incomplete count recovery ( CRi ) , patient receive decitabine , filgrastim , cladribine cytarabine Arm I . Treatment repeat every 10 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month every 3 month 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>For patient newly diagnose disease : diagnosis `` highgrade '' MDS ( &gt; = 10 % blast morphology ) AML acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ( q22 ; q12 ) variant accord 2016 World Health Organization ( WHO ) classification ; patient relapsed/refractory disease : prior diagnosis `` highrisk '' MDS nonAPL AML , relapsed/refractory disease accord 2003 recommendation International Working Group , require first subsequent salvage therapy ; patient mixed phenotype acute leukemia ( MPAL ) eligible Outside diagnostic material acceptable long peripheral blood and/or bone marrow slide review study institution ; flow cytometric analysis peripheral blood and/or bone marrow perform accord institutional practice guideline Patients prior autologous allogeneic hematopoietic cell transplantation ( HCT ) eligible relapse occur provide symptom graftversus host disease well control stable use immunosuppressive agent Treatmentrelated mortality ( TRM ) score = &lt; 9.2 calculate simplified model Should active therapy AML exception hydroxyurea least 14 day prior study registration unless patient rapidly progressive disease , grade 24 nonhematologic toxicity resolve May previously receive monotherapy demethylating agent MDS AML treatment mitoxantrone cladribinebased regimen MDS AML , include GCLAM , demethylating agent prim combination chemotherapy Patients symptoms/signs hyperleukocytosis white blood cell ( WBC ) &gt; 100,000/uL treated leukapheresis may receive 2 dos cytarabine ( 500 mg/m^2/dose ) prior enrollment Bilirubin = &lt; 2.5 x institutional upper limit normal ( IULN ) unless elevation thought due hepatic infiltration AML , Gilbert 's syndrome , hemolysis ( assess within 14 day prior registration ) Serum creatinine = &lt; 2.0 mg/dL ( assess within 14 day prior registration ) Left ventricular ejection fraction &gt; = 45 % , assess within 3 month prior registration , e.g . multigated acquisition scan ( MUGA ) scan echocardiography , appropriate diagnostic modality clinical evidence congestive heart failure ; patient anthracyclinebased therapy since recent cardiac assessment , cardiac evaluation repeat clinical radiographic suspicion cardiac dysfunction , previous cardiac assessment abnormal Women childbearing potential men must agree use adequate contraception Ability understand willingness sign write consent Refractory/relapsing myeloid blast crisis chronic myeloid leukemia ( CML ) , unless patient consider candidate tyrosine kinase inhibitor treatment Concomitant illness associate likely survival &lt; 1 year Active systemic fungal , bacterial , viral , infection , unless disease treatment antimicrobial and/or control stable ( e.g . specific , effective therapy available/feasible desire [ e.g . chronic viral hepatitis , human immunodeficiency virus ( HIV ) ] ) ; patient need clinically stable define afebrile hemodynamically stable 2448 hour Known hypersensitivity study drug Pregnancy lactation Patients may receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>